Simulations Plus (SLP) Q3 2025: Backlog Jumps 18%, Signaling Deferred Services Demand
Simulations Plus delivered another quarter of double-digit revenue growth, but the most telling signal was an 18% sequential increase in services backlog, highlighting customer caution and a pronounced push of project starts into the back half of the year. The company’s software business remains resilient, buoyed by robust renewal rates and high-value QSP licenses, while services revenue timing reflects ongoing macro headwinds in biopharma spend. Management reaffirmed full-year guidance and stressed operational discipline, but margin compression and evolving seasonality warrant close attention as SLP’s acquisition integration and cross-sell ambitions unfold.
Summary
- Backlog Expansion: Deferred project starts drove a sharp increase in services backlog, underscoring client caution.
- Software Stability: Recurring software revenue and high retention rates insulated results from biopharma budget pressure.
- Margin Watchpoint: Cost absorption from acquisitions and services mix diluted gross margin, pressuring profitability targets.
Performance Analysis
Simulations Plus posted strong top-line growth, with total revenue up 23% year over year, driven by software and the contribution of the recently acquired ALI and Medical Communications (MC) units. Software comprised 60% of revenue, led by GastroPlus (PBPK modeling software), Monolix Suite, and AdMet Predictor. Notably, Quantitative Systems Pharmacology (QSP) software revenue surged 89% due to a major atopic dermatitis model license, but management cautioned that such deals are lumpy and not indicative of a new run-rate. Average software revenue per customer increased to $124,000, reflecting successful upselling and cross-sell initiatives.
In services, revenue was up 34%, but this included inorganic contributions; organic growth was flat as clients delayed project starts despite strong bookings. The backlog reached $20.4 million, up 18% sequentially and 13% year over year, with most growth in the CPP and MC business units. Gross margin fell to 59%, down from 72% a year ago, as services mix and acquisition-related amortization weighed on profitability. The software gross margin remained robust at 81%, but services gross margin dropped to 25%, reflecting higher cost absorption and expense reclassification.
- Backlog Accumulation: Services backlog rose sharply as clients contracted but deferred project initiation, pushing revenue into later quarters.
- Renewal Rates Hold: Software fee-based renewal rate dipped to 90% due to a large delayed renewal, but account-based rates remained stable, supporting recurring revenue visibility.
- Margin Compression: Total gross margin declined as acquired business costs and services mix diluted profitability, highlighting integration and cost control challenges.
The quarter’s performance underscores the dichotomy between stable software demand and more volatile, delayed services execution, with margin headwinds from recent acquisitions and evolving revenue mix.
Executive Commentary
"Our strong second quarter results reflected solid performance in both our software and services segment. The team executed well in the first half of the year, and our results are in line with our guidance, despite the persistent cost-constrained and limited funding environment that our customers have been facing for some time."
Sean O'Connor, Chief Executive Officer
"We remain well capitalized with no debt and strong free cash flow to execute our growth strategy."
Will Frederick, Chief Financial Officer and Chief Operating Officer
Strategic Positioning
1. Software as Infrastructure Anchor
SLP’s software segment acts as a mission-critical infrastructure layer for biopharma R&D, evidenced by high renewal rates and resilient demand even as clients curb discretionary spend. The company’s portfolio—anchored by GastroPlus, Monolix Suite, and AdMet Predictor—enables modeling, simulation, and predictive analytics, positioning SLP as a core partner in drug development workflows. The QSP business unit’s lumpy but high-ticket licenses, such as the atopic dermatitis model, further reinforce the strategic value proposition to large pharma clients.
2. Services Backlog and Deferred Revenue
The 18% sequential jump in backlog signals robust demand for SLP’s services, but also highlights clients’ ongoing hesitancy to initiate projects amid macro and funding uncertainty. While bookings are strong, actual revenue recognition is increasingly back-half weighted, altering historical seasonality and introducing execution risk if project ramps are delayed further or if SLP’s capacity is stretched by simultaneous starts.
3. Acquisition Integration and Cross-Selling
Recent acquisitions—ALI and MC— are being integrated and rebranded (ALI as Proficiency), with management emphasizing cross-sell opportunities into the existing client base. Early pipeline activity is promising, but revenue contribution is still ramping and seasonality remains less predictable than legacy software. The $5 million MC contract demonstrates potential for larger, multi-year deals, but does not yet change overall segment guidance, implying a conservative outlook on immediate synergy realization.
4. Margin Management and Cost Structure
Gross margin contraction is a central theme, as software margins remain high but services and acquisition-related costs drag consolidated profitability. Management is targeting a return to historical adjusted EBITDA margins of 35% to 40%, but acknowledges this will require both top-line growth and tighter cost control, particularly as service mix grows and integration costs are absorbed.
5. Industry and Regulatory Positioning
SLP is insulated from direct federal funding risk (e.g., NIH cuts), as its software is provided free to academia and current revenue is not exposed to academic grants. Management sees minimal impact from FDA disruption or tariffs in the near term, but acknowledges that global biopharma caution—driven by regulatory, funding, and geopolitical factors—remains a persistent headwind for project starts and spending velocity.
Key Considerations
The quarter reflects a business in transition, balancing recurring software strength with acquisition integration and services execution risk.
Key Considerations:
- Services Revenue Timing: A growing backlog signals future revenue but also raises execution and timing risk if project starts are further delayed.
- Margin Sensitivity: Gross margin dilution from services mix and acquisition amortization puts pressure on profitability targets, requiring disciplined cost management.
- Cross-Selling Leverage: The integration of ALI and MC expands SLP’s cross-sell potential, but realization depends on execution and client adoption pacing.
- Seasonality Shift: Acquisitions and deferred services revenue are flattening historical seasonality, making quarterly forecasting more complex and increasing the importance of backlog conversion.
Risks
SLP faces execution risk from delayed services project starts, which could compress margins or miss revenue targets if backlogged work is not converted as planned. Acquisition integration introduces cost and operational complexity. Macroeconomic, regulatory, and funding headwinds in biopharma may further slow client spending or extend sales cycles, increasing the risk of uneven quarterly results and margin volatility.
Forward Outlook
For Q4, Simulations Plus guided to:
- Sequential revenue step-up, with Q3 expected to be 25% of full-year revenue and Q4 higher
- Year-over-year Q3 growth of 21% to 25%
For full-year 2025, management reaffirmed guidance:
- Total revenue of $90–93 million
- ALI and MC contribution of $15–18 million
- Adjusted EBITDA margin of 31%–33%
- Adjusted diluted EPS of $1.07–$1.20
Management cited strong bookings, ramping acquisition contribution, and operational discipline as key drivers, while reiterating the goal of returning to historical margin levels as integration progresses.
- Backlog conversion and project timing will drive quarterly results
- Margin improvement hinges on cost control and cross-sell execution
Takeaways
Investors should focus on SLP’s ability to convert backlog to revenue, manage margin pressure, and realize cross-sell synergies as acquisitions ramp. The software business remains a stable anchor, but services execution and cost control will dictate near-term valuation and long-term growth trajectory.
- Deferred Services Demand: The sharp backlog increase reflects pent-up demand but also heightens execution risk if client caution persists or capacity is stretched.
- Integration Complexity: Margin dilution and evolving seasonality signal that acquisition integration will remain a key focus, with full benefits yet to be realized.
- Forward Watchpoint: Investors should monitor backlog conversion rates, margin recovery, and the pace of cross-sell adoption in upcoming quarters.
Conclusion
Simulations Plus is navigating a complex environment with resilient software demand and growing backlog, but faces margin pressure and execution risk as it integrates acquisitions and manages deferred services revenue. The next quarters will test SLP’s ability to deliver on its cross-sell strategy and margin recovery ambitions while maintaining its software growth trajectory.
Industry Read-Through
SLP’s quarterly dynamics mirror broader trends in the life sciences software and services sector, where core platforms remain sticky but services demand is pushed to later periods due to client budget caution. Backlog growth and margin compression are likely to be recurring themes for peers with mixed software-services models and recent acquisitions. The shift in seasonality and reliance on backlog conversion signal that investors across the sector should scrutinize deferred revenue and margin trends, especially as biopharma clients continue to manage spend with caution and regulatory uncertainty persists.